Lipocine Inc
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
LPCN$1.71+5.6%Stored close · as of Nov 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Checking your notes…
| Years Ended December 31, | ||||
|---|---|---|---|---|
| 2023 · 2022 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $(16,352,082) | $(10,758,636) | ||
| Adjustments to reconcile net loss to cash used in operating activities: | ||||
| Depreciation expense | 28,661 | 9,453 | ||
| Stock-based compensation expense | 654,438 | 636,140 | ||
| Non-cash interest expense | - | 5,842 | ||
| Non-cash gain on change in fair value of warrant liability | (212,690) | (565,940) | ||
| Gain on settlement of litigation liability | - | (250,000) | ||
| Amortization of discounts on marketable investment securities | (952,651) | (122,048) | ||
| Write off of contract asset due to variable consideration revenue reversal | 2,960,805 | - | ||
| Changes in operating assets and liabilities: | ||||
| Accrued interest income | 28,173 | 166,826 | ||
| Contract asset | 709,933 | 218,072 | ||
| Prepaid and other current assets | 333,085 | 569,146 | ||
| Accounts payable | 795,589 | (688,954) | ||
| Accrued expenses | 140,748 | 61,280 | ||
| Litigation settlement liability | - | (1,250,000) | ||
| Cash used in operating activities | (11,865,991) | (11,968,819) | ||
| Cash flows from investing activities: | ||||
| Purchase of property and equipment | (13,167) | (133,831) | ||
| Purchases of marketable investment securities | (22,902,147) | (45,074,462) | ||
| Maturities of marketable investment securities | 36,000,000 | 59,502,000 | ||
| Cash provided by investing activities | 13,084,686 | 14,293,707 | ||
| Cash flows from financing activities: | ||||
| Debt repayments | - | (1,666,667) | ||
| End of loan payment | - | (650,000) | ||
| Net proceeds from sale of common stock through ATM | 404,567 | (21,700) | ||
| Proceeds from stock option exercises | - | 211,423 | ||
| Cash provided by (used in) financing activities | 404,567 | (2,126,944) | ||
| Net increase in cash and cash equivalents | 1,623,262 | 197,944 | ||
| Cash and cash equivalents at beginning of period | 3,148,496 | 2,950,552 | ||
| Cash and cash equivalents at end of period | $4,771,758 | $3,148,496 | ||
| Supplemental disclosure of cash flow information: | ||||
| Interest paid | $ | - | $21,256 | |
| Income taxes paid | $225 | 200 | ||
| Supplemental disclosure of non-cash investing and financing activity: | ||||
| Net unrealized gain (loss) on available-for-sale securities | $27,580 | $(2,305) | ||
| Accrued final payment charge on debt | $ | - | $5,842 | |
| Issuance of Series B preferred stock | $89 | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.